Cryo-Cell International, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $36.7M
- Price
- $4.56
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.09%
- Volume
- 51.4K
About
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Quick stats
Shares outstanding8.1M
Computed float3.7M
Float / shares46.1%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000862692
Websitehttps://www.cryo-cell.com
AI Summary
AI-generated1/7
minormixedearnings
Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2026 Financial Results
Cryo-Cell reported fiscal Q2 2026 revenue of $7.8 million, a 2% decrease from the prior year's $7.9 million.
Despite the revenue decline, net income improved to $555,000, or $0.07 per share, compared to $356,000, or $0.04 per share, in the same period last year.
The company operates as a private cord blood bank and holds exclusive rights to the PrepaCyte-CB processing technology, maintaining its focus on regenerative medicine.
Red flags
- Revenue declined 2% year-over-year